{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-335200","form_type":"8-K","ticker":"BTMD","cik":"0001819253","company_name":"biote Corp.","filed_at":"2026-08-05T20:20:16+00:00","discovered_at":"2026-08-05T20:21:01.267320+00:00","generated_at":"2026-08-05T20:21:11.632506+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biote Q2 2026 revenue $44.2M (-9.5% YoY); net loss $(7.4)M vs net income $3.9M; updates full-year outlook","bullets":["Revenue $44.2M (-9.5% YoY); procedure revenue $30.3M (-13.9%) due to voluntary recall of Asteria Health pellets.","Net loss $(7.4)M ($0.23 diluted loss per share) vs net income $3.9M ($0.10 EPS) in Q2 2025.","Adjusted EBITDA $5.6M (12.6% margin); gross margin 65.4% vs 71.6% due to recall costs.","Dietary supplements revenue grew 5.7% to $11.4M.","Company updated full-year 2026 outlook; specifics not provided in excerpt."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-335200","json":"https://secwatch.observer/filing/0001193125-26-335200.json","markdown":"https://secwatch.observer/filing/0001193125-26-335200.md","text":"https://secwatch.observer/filing/0001193125-26-335200.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819253/000119312526335200/0001193125-26-335200-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819253/000119312526335200/btmd-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:21:11.632506+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}